These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2248078)

  • 41. Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.
    Botte L; Evrard JL; Gilles C; Stenier P; Wolfrum C
    Acta Psychiatr Belg; 1992; 92(6):355-69. PubMed ID: 1345409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study.
    Rimón R; Jääskeläinen J; Kaartinen P; Kalli A; Kilponen E; Koskinen T; Nikkilä H; Pirttiperä V; Seppälä J
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):141-7. PubMed ID: 8468435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of a reversible monoamine oxidase-A inhibitor versus imipramine in subgroups of depressed patients.
    Bizière K; Berger M
    Acta Psychiatr Scand Suppl; 1990; 360():59-60. PubMed ID: 2248074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Moclobemide in the long-term treatment of depressed patients].
    Carl G; Laux G
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():48-50. PubMed ID: 2511580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
    Kennedy SH
    J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. UK Moclobemide Study Group.
    Int Clin Psychopharmacol; 1994; 9(2):109-13. PubMed ID: 8056992
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Moclobemide versus clomipramine in the treatment of depression: a multicentre trial in Spain.
    Civeira J; Cervera S; Giner J; Allen SR; Hellstern K; Malanowski H; Wirz R; Klar K
    Acta Psychiatr Scand Suppl; 1990; 360():48-9. PubMed ID: 2248070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, tolerability and efficacy of the reversible monoamine oxidase inhibitor RS-8359 in early clinical trials.
    Püchler K; Plenker A; Volz HP
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 5():S31-6. PubMed ID: 9466167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Moclobemide safety: monitoring a newly developed product in the 1990s.
    Hilton S; Jaber B; Ruch R
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):76S-83S. PubMed ID: 7593735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing the economic value of a new antidepressant. A willingness-to-pay approach.
    O'Brien BJ; Novosel S; Torrance G; Streiner D
    Pharmacoeconomics; 1995 Jul; 8(1):34-45. PubMed ID: 10155600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation.
    Jouvent R; Le Houezec J; Payan C; Mikkelsen H; Fermanian J; Millet V; Dufour H
    Psychiatry Res; 1998 Jul; 79(3):267-75. PubMed ID: 9704873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of moclobemide in endogenous depression: a survey of recent data.
    Woggon B
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):137-9. PubMed ID: 8468434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Moclobemide and clomipramine in endogenous depression. A randomized clinical trial.
    Koczkas C; Holm P; Karlsson A; Nagy A; Ose E; Pétursson H; Ulverås L; Wenedikter O
    Acta Psychiatr Scand; 1989 Jun; 79(6):523-9. PubMed ID: 2669440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
    Gieschke R; Schmid-Burgk W; Amrein R
    J Neural Transm Suppl; 1988; 26():97-104. PubMed ID: 3283292
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
    J Affect Disord; 1993 Jun; 28(2):105-16. PubMed ID: 8354766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New antidepressants: use in high-risk patients.
    Hale AS
    J Clin Psychiatry; 1993 Aug; 54 Suppl():61-70; discussion 71-3. PubMed ID: 8253707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
    Tiller JW; Maguire KP; Davies BM
    Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction between moclobemide and oral tyramine in depressed patients.
    Burgess CD; Mellsop GW
    Fundam Clin Pharmacol; 1989; 3(1):47-52. PubMed ID: 2714732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe adverse reaction to moclobemide.
    O'Kane GM; Gottlieb T
    Lancet; 1996 May; 347(9011):1329-30. PubMed ID: 8622519
    [No Abstract]   [Full Text] [Related]  

  • 60. Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany.
    Funke HJ; Moritz E; Hellstern K; Malanowski H
    Acta Psychiatr Scand Suppl; 1990; 360():46-7. PubMed ID: 2248069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.